Advertisement

BMC Pharmacology

, 7:A63 | Cite as

Control of hepatocellular apoptosis by cytokines (TGF-β1), liver tumor promoter (phenobarbital) and nutritional factors (glucose): approach to validate the hepatoma cell line HCC-1.2 as cell culture model

  • Anneliese Karwan
  • Julia Dornetshuber
  • Rolf Schulte-Hermann
  • Wilfried Bursch
Open Access
Meeting abstract
  • 871 Downloads

Keywords

Phenobarbital Cell Culture System Hepatoma Cell Line Cell Culture Model Intrinsic Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Since a long line of years we have studied liver growth regulation (cell proliferation, apoptosis) in vivo. One of the prominent findings was that TGF-β1 constitutes a major death signal in rat liver, acting in concert with nutritional factors to maintain liver cell number homeostasis. Toxicological tests with rodents in vivo showed that liver tumor promoter (e.g. phenobarbital) favour cell multiplication and inhibit apoptosis, thereby accelerating hepatocarcinogenesis. To elucidate their mode of action (MOA), along with the general need for alternative test models in toxicology, we searched for a liver cell culture system yielding a high concordance with our in vivo findings. Here we report on a newly established cell line HCC-1.2 [Grasl-Kraupp et al., submitted] exhibiting the following features: (1) a high sensitivity towards the anti-proliferative and pro-apoptotic action of TGF-β1; (2) apoptosis is mediated via the intrinsic pathway as demonstrated by caspase analysis; (3) inhibition of TGF-β1-induced apoptosis by liver tumor promoter, as exemplified by phenobarbital; (4) glucose withdrawal exerts an additive effect to the pro-apoptotic action of TGF-β1, all of which agree with our previous in vivo observations on liver growth regulation. Thus, our observations suggest that the HCC-1.2 cells constitute a valid test system as it meets well with prerequists for further studies tackling the MOA of liver tumor promoter, along with their interaction with nutritional factors.

Copyright information

© Karwan et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • Anneliese Karwan
    • 1
  • Julia Dornetshuber
    • 1
  • Rolf Schulte-Hermann
    • 1
  • Wilfried Bursch
    • 1
  1. 1.Department of Medicine I, Institute of Cancer Research, Research Unit Toxicology and PreventionMedical University of ViennaAustria

Personalised recommendations